FDA & Government News

May 18, 2026

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

Conexiant

May 15, 2026

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

Kff Health News

April 28, 2026

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

Conexiant

April 24, 2026

Dupilumab Gains Pediatric CSU Approval

Targets type 2 inflammation in a population with limited treatment options

Conexiant

April 10, 2026

Injectable Targets Décolleté Wrinkles

New indication expands use of injectable biostimulator beyond the face.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

April 02, 2026

CDC Lists Dozens of Infectious Disease Tests as Unavailable

More than two dozen assays paused or discontinued, with alternative testing options noted

Conexiant

March 27, 2026

FDA Drops Age Limit for Neffy

Needle-free epinephrine expands access for younger children meeting weight criteria

Conexiant

March 26, 2026

St. Louis Pediatrician Gets 20-Year Sentence

A physician exploited patients with addiction for nearly a decade, trading prescriptions for sex acts, photos, and cash

Conexiant

March 18, 2026

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

Conexiant

March 17, 2026

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

In topline results from Lilly’s ADorable-1 trial, pediatric patients aged 6 months to 18 years had higher rates of skin clearance and itch improvement vs placebo, according to a press release from Eli Lilly and Company.

Conexiant

Ivarmacitinib Eased Refractory PCA: Case Report

FDA & Government News

FDA Clears Golimumab Biosimilars

Why FDA Said No to a Melanoma Drug

FDA Clears Self-Administered Lupus Therapy

Dupilumab Gains Pediatric CSU Approval

Injectable Targets Décolleté Wrinkles

Daily News

CDC Lists Dozens of Infectious Disease Tests as Unavailable

FDA Drops Age Limit for Neffy

St. Louis Pediatrician Gets 20-Year Sentence

FDA Approves New Oral Option for Plaque Psoriasis

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

Recommendations

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Trending Now

Ivarmacitinib Eased Refractory PCA: Case Report

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dental Technology

Inside Dentistry

The ASCO Post

JADPRO

JNCCN

JNCCN 360

Corneal Physician

Glaucoma Physician

New Retinal Physician

Ophthalmology Management

Ophthalmic Professional

Presbyopia Physician

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

Presbyopia Physician

The New Optometrist

The Pathologist

FDA & Government News

Daily News

Recommendations